Moreover, anlotinib pretreatment also hindered the engraftment of hCD45+CD34+ cells in the bone marrow (Figure 3H).Collectively, anlotinib effectively suppressed the regeneration capacity of LSCs derived from AML patients regardless the phenotype of LSCs. Here, CD34 is linked to acute myeloid leukemia.